|
⚲
|
| Keyboard |
| ProQuest Associates III LLC
✚
|
|
|---|---|
| CIK # | 0001306134 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| UroGen Pharma Ltd | 37.3 | ||
| Holdings by Sector ($M) |
|---|
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-NT | [0001306134] | |
| 3 | [0001306134] | |
| 4 | [0001306134] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Agile Therapeutics Inc AGRX
Common Stock
|
2016-01-27 | Buy | 393,700 | $6.35 | 2,499,995 |
|
Agile Therapeutics Inc AGRX
Common Stock
|
2015-01-23 | Buy | 811,966 | $5.85 | 4,750,001 |
|
Agile Therapeutics Inc AGRX
Common Stock
|
2014-05-29 | Conversion | 1,950,200 | ||
|
Agile Therapeutics Inc AGRX
Common Stock
|
2014-05-29 | Conversion | 460,350 | ||
|
Agile Therapeutics Inc AGRX
Common Stock
|
2014-05-29 | Conversion | 158,174 | $6.00 | 949,044 |
|
Agile Therapeutics Inc AGRX
Common Stock
|
2014-05-29 | Buy | 1,120,833 | $6.00 | 6,724,998 |
|
Agile Therapeutics Inc AGRX
Warrants (right to buy) · derivative
|
2014-05-29 | Other | 141,825 | $0.00 | |
|
Agile Therapeutics Inc AGRX
Series C Preferred Stock · derivative
|
2014-05-29 | Conversion | 328,821 | $0.00 | |
|
Agile Therapeutics Inc AGRX
Series B Preferred Stock · derivative
|
2014-05-29 | Conversion | 1,393,000 | $0.00 | |
|
Agile Therapeutics Inc AGRX
Series A-1 Preferred Stock · derivative
|
2014-05-29 | Conversion | 117,441 | $0.00 | |
|
Agile Therapeutics Inc AGRX
Convertible Subordinated Notes · derivative
|
2014-05-29 | Conversion | $0.00 | ||
|
Agile Therapeutics Inc AGRX
Common Stock
|
2014-05-29 | Conversion | 164,417 | ||
|
Novadel Pharma Inc NVDL
Series A Warrants to Purchase Common Stock · derivative
|
2011-04-04 | Other | 14,696,117 | $0.00 |